Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
26 February 2018 |
Main ID: |
EUCTR2011-002331-25-IT |
Date of registration:
|
16/04/2012 |
Prospective Registration:
|
No |
Primary sponsor: |
|
Public title:
|
A randomized, multicenter, open-label study evaluating two different doses of pertuzumab in patients with HER2-positive advanced gastric cancer
|
Scientific title:
|
An Open-Label, Randomized, Multicenter Phase IIa Study Evaluating Pertuzumab in Combination with Trastuzumab and Chemotherapy in Patients with HER2-Positive Advanced Gastric Cancer - JOSHUA |
Date of first enrolment:
|
08/09/2011 |
Target sample size:
|
30 |
Recruitment status: |
Not Recruiting |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-002331-25 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: yes Randomised: yes Open: yes Single blind: no Double blind: no Parallel group: yes Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: no Placebo: no Other: yes Other specify the comparator: Two different dosing schemes of pertuzumab will be Number of treatment arms in the trial: 2
|
Phase:
|
Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): no
|
|
Countries of recruitment
|
Belgium
|
Czech Republic
|
Germany
|
Italy
|
Korea, Democratic People's Republic of
|
Korea, Republic of
|
Netherlands
|
Spain
|
Contacts
|
Name:
|
Medical Affairs&Clinical Operations
|
Address:
|
Viale G.B. Stucchi, 110
20900
Monza
Italy |
Telephone:
|
039/2475070 |
Email:
|
sergio.scaccabarozzi@roche.com |
Affiliation:
|
Roche S.p.A. |
|
Name:
|
Medical Affairs&Clinical Operations
|
Address:
|
Viale G.B. Stucchi, 110
20900
Monza
Italy |
Telephone:
|
039/2475070 |
Email:
|
sergio.scaccabarozzi@roche.com |
Affiliation:
|
Roche S.p.A. |
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: Disease-Specific Inclusion Criteria • Histologically confirmed adenocarcinoma of the stomach or gastroesophageal junction with inoperable locally advanced or metastatic disease, not amenable to curative therapy. Patients with advanced disease who present with a recurrence post operatively (when intent of surgery was cure) are also eligible for entry. • Measurable disease, according to the Response Evaluation Criteria in Solid Tumors (RECIST), v1.1, assessed using imaging techniques (CT or MRI), or non-measurable disease that can be followed • HER2 positive tumor defined as either IHC 3+ or IHC 2+ in combination with ISH +, as assessed by central laboratory on primary or metastatic tumor ISH positivity is defined as a ratio of >= 2.0 for the number of HER2 gene copies to the number of signals for CEP17. Availability of formalin-fixed paraffin-embedded (FFPE) tissue with at least 5 mm of invasive tumor for central confirmation of HER2 eligibility is mandatory. • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 • Baseline LVEF >= 55% (measured by ECHO or MUGA) • Life expectancy of at least 3 months. General Inclusion Criteria • Male or female • Age >= 18 years • Signed informed consent • For women of childbearing potential and male participants with partners of childbearing potential: agreement to use a highly effective non-hormonal form of contraception or two effective forms of nonhormonal contraception by the patient and/or partner (see Section 7.2.6 for details). Contraception use must continue for the duration of study treatment and for at least 6 months after the last dose of study medication. Are the trial subjects under 18? no Number of subjects for this age range: 0 F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 15 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 15
Exclusion criteria: Cancer-Related Exclusion Criteria • Previous chemotherapy for advanced or metastatic disease, except that prior adjuvant or neoadjuvant therapy is allowed if at least 6 months has elapsed between completion of adjuvant or neoadjuvant therapy and enrollment in the study. Adjuvant or neoadjuvant treatment with platinum-based therapy is not allowed. • Lack of physical integrity of the upper gastrointestinal tract or malabsorption syndrome(e.g., patients with partial or total gastrectomy can enter the study, but not those with a jejunostomy probe) • Active (significant or uncontrolled) gastrointestinal bleeding • Residual relevant toxicity resulting from previous therapy(e.g., neurological toxicity of >= Grade >= 2 [NCI CTCAE])with the exception of alopecia • Other malignancy within the last 5 years, except for carcinoma in situ of the cervix, or basal cell carcinoma. Exclusion Criteria Related to Hematological, Biochemical, and Organ Function • Any of the following abnormal laboratory tests immediately prior to randomization: Serum total bilirubin > 1.5 times the upper limit of normal (ULN) or, for patients with known Gilberts syndrome, serum total bilirubin > 2 × ULN; For patients with no liver and no bone metastases:AST or ALT > 2.5 × ULN, and alkaline phosphatase (ALP) > 2.5 × ULN; In patients with liver metastases and no bone metastases:AST or ALT >5 ×ULN, and ALP > 2.5 × ULN; In patients with liver metastases and bone metastases:AST or ALT >5 × ULN, and ALP >10 × ULN; In patients with bone metastases and no liver metastases:AST or ALT >2.5 ×ULN, and ALP >10 × ULN; Albumin < 25 g/L; Creatinine clearance < 60 mL/min; Total WBC count <2500/µL(<2.5 × 109/L); Absolute neutrophil count (ANC) <1500/µL (<1.5 × 109/L); Platelets < 100,000/µL (<100 × 109/L). Other Study Drug–Related Exclusion Criteria: • Serious cardiac illness or medical conditions including but not confined to: History of documented heart failure or systolic dysfunction (LVEF < 50%); High-risk uncontrolled arrhythmias, such as atrial tachycardia with a heart rate >= 100/min at rest, significant ventricular arrhythmia (ventricular tachycardia) or higher-grade AV block (second-degree AV block Type 2 [Mobitz II] or third-degree AV block); Angina pectoris requiring anti-anginal medication; Clinically significant valvular heart disease; Evidence of transmural infarction on ECG; Poorly controlled hypertension(e.g., systolic blood pressure >180 mmHg or diastolic blood pressure >100 mmHg). • Dyspnea at rest due to complications of advanced malignancy or other disease, or requirement for supportive oxygen therapy. • Treatment with chronic or high-dose corticosteroid therapy. Inhaled steroids and short courses of oral steroids for anti-emesis or as an appetite stimulant are allowed. • Clinically significant hearing abnormality. • Known dihydropyrimidine dehydrogenase deficiency. General Exclusion Criteria • History or clinical evidence of brain metastases. • Serious uncontrolled systemic intercurrent illness (e.g., infections or poorly controlled diabetes). • Pregnant or lactating. Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to randomization, irrespective of the method of contraception used. • Radiotherapy within 4 weeks prior to start of study treatment, or within 2 weeks prior to start of study treatment if palliative radiotherapy is given to bone metastatic site peripherally and
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
Therapeutic area: Diseases [C] - Cancer [C04]
|
HER2-positive adenocarcinoma of the stomach or gastroesophageal junction MedDRA version: 14.1
Level: PT
Classification code 10061968
Term: Gastric neoplasm
System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
|
Intervention(s)
|
Product Name: Pertuzumab (rhuMAb 2C4) Product Code: Ro 436-8451/F01 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: PERTUZUMAB CAS Number: 380610275 Current Sponsor code: RO4368451 Other descriptive name: rhuMAb 2C4 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 420-
Trade Name: Herceptin® Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: TRASTUZUMAB CAS Number: 180288-69-1 Current Sponsor code: Ro 45-2317 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150-
|
Primary Outcome(s)
|
Secondary Objective: To make an exploratory assessment of the anti-tumor activity of pertuzumab in combination with trastuzumab and chemotherapy in patients with HER2 positive inoperable locally advanced or recurrent and/or metastatic adenocarcinoma of the stomach or gastroesophageal junction
|
Main Objective: • To estimate the minimum (trough) pertuzumab concentration (Cmin) at Day 43 for two dose levels of pertuzumab in order to identify a dose that produces a steady-state Cmin of = 20 µg/mL in 90% of patients receiving pertuzumab and trastuzumab plus chemotherapy as first-line treatment for HER2-positive inoperable locally advanced or recurrent and/or metastatic adenocarcinoma of the stomach or gastroesophageal junction • To evaluate the safety and tolerability of two dose levels of pertuzumab in combination with trastuzumab and chemotherapy administered every 3 weeks to patients with HER2-positive inoperable locally advanced or recurrent and/or metastatic adenocarcinoma of the stomach or gastroesophageal junction
|
Primary end point(s): Minimum (trough) serum concentration (Cmin) for pertuzumab
|
Timepoint(s) of evaluation of this end point: Day 43
|
Secondary Outcome(s)
|
Timepoint(s) of evaluation of this end point: End of cyles 3 and 6
|
Secondary end point(s): This study is not designed or powered to provide an accurate evaluation of efficacy. Thus, efficacy analyses are exploratory and no comparisons between dose levels will be made. Investigator-assessed tumor response will be used to summarize best overall response at the end of Cycles 3 and 6 for each treatment arm, defined as patients with a complete or partial response as determined by RECIST.
|
Secondary ID(s)
|
BP27836
|
2011-002331-25-DE
|
Source(s) of Monetary Support
|
F. Hoffmann-La Roche Ltd.
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|